Skip to content
    VRTX
    Earnings call· Mar 2026(Q1 FY26)

    VERTEX PHARMACEUTICALS INC / MA Q1 FY26 earnings call VRTX

    May 4, 2026 Source

    Executive summary

    Vertex Pharmaceuticals Q1 FY26 — Strong Growth Across Portfolio and Rapid Pipeline Advancement

    Vertex Pharmaceuticals delivered a strong Q1 FY26, marked by 8% revenue growth driven by its CF portfolio and significant contributions from new disease areas like CASGEVY and JOURNAVX. The company achieved rapid progress in its pipeline, notably with the "sparkling" Phase III IgAN data for Pove leading to a swift BLA submission, and advancements in other renal programs and type 1 diabetes. While the VX-522 program was discontinued due to tolerability issues, Vertex remains committed to addressing the remaining unmet needs in CF and expanding its therapeutic franchises.

    Highlights

    5
    • Total product revenue grew 8% year-on-year to $2.99 billion.

    • ALYFTREK exceeded $1 billion in cumulative revenue since its launch.

    • CASGEVY initiated treatment for over 500 patients, and JOURNAVX surpassed 1 million prescriptions written.

    • New disease areas (CASGEVY and JOURNAVX) drove approximately 25% of total product revenue growth.

    • Pove Phase III RAINIER study in IgAN showed "sparkling" efficacy and safety, leading to the fastest BLA submission in Vertex history (27 days).

    Concerns

    1
    • Discontinuation of the VX-522 mRNA therapy program due to unresolved tolerability issues (lung inflammation).

    Guidance & targets

    8
    CategoryTargetConfidence
    Total revenue
    $12.95 billion to $13.1 billion
    high materiality
    High
    Non-CF products revenue
    $500 million or more
    medium materiality
    High
    Gross margin
    just under 86%
    medium materiality
    High
    Combined non-GAAP operating expense
    $5.65 billion to $5.75 billion
    medium materiality
    High
    Non-GAAP effective tax rate
    19.5% to 20.5%
    low materiality
    High
    JOURNAVX prescriptions
    more than triple the 550,000 prescriptions from 2025
    medium materiality
    High
    JOURNAVX revenue growth
    significantly exceed prescription growth
    medium materiality
    High
    JOURNAVX gross to net
    normalize
    medium materiality
    High

    Segment performance

    2
    SegmentRevenueYoYQoQMargin
    Global CF
    Growth balanced between U.S. and international markets. ALYFTREK uptake continues to resonate, surpassing $1 billion in cumulative global revenue. Label expansions for ALYFTREK and TRIKAFTA represent a meaningful incremental commercial opportunity of approximately 800 newly eligible CF patients in the U.S.
    US revenue growth: 5% YoYInternational revenue growth: 8% YoY
    6%
    New Disease Areas (Non-CF)
    CASGEVY rollout gathering momentum, with over 500 patients initiating treatment. JOURNAVX prescriptions and awareness continue to build, with over 1 million prescriptions written since launch and 350,000 filled in Q1.
    CASGEVY revenue: $43 millionJOURNAVX revenue: $29 millionContribution to total product revenue growth: ~25%

    Operational metrics

    36
    Trial discontinuations (placebo)
    1.5%
    Q1 FY26

    Rate of trial discontinuations in the placebo group of the Pove IgAN RAINIER study.

    Trial discontinuations (Pove)
    0.8%
    Q1 FY26

    Rate of trial discontinuations in the Pove group of the Pove IgAN RAINIER study.

    Non-GAAP Operating Income
    $1.31 billionincreased from $1.18 billion YoY
    Q1 FY26

    Non-GAAP operating income for the first quarter of 2026.

    Non-GAAP Operating Income (prior year)
    $1.18 billion
    Q1 FY25

    Non-GAAP operating income for the first quarter of 2025, used as a baseline for year-over-year comparison.

    Non-GAAP Net Income
    $1.1 billionincreased by $93 million YoY
    Q1 FY26

    Non-GAAP net income for the first quarter of 2026.

    Non-GAAP Net Income Increase
    $93 millionYoY increase
    Q1 FY26

    Year-over-year increase in non-GAAP net income for the first quarter of 2026.

    Cash and Investments Balance
    $13 billion
    Q1 FY26 end

    Total cash and investments balance at the end of the first quarter.

    Shares Repurchased
    741,000 shares
    Q1 FY26

    Number of shares repurchased during the first quarter.

    Share Buyback Amount
    $344 million
    Q1 FY26

    Amount deployed for share repurchases in the first quarter.

    Combined non-GAAP R&D, Acquired IP R&D, SG&A expenses
    $1.29 billionincreased 5% YoY
    Q1 FY26

    Combined non-GAAP operating expenses for the first quarter.

    Non-GAAP R&D expenses (standalone)
    down 2% YoY
    Q1 FY26

    Year-over-year change in non-GAAP R&D expenses, partly due to timing and mix of clinical trial expenses.

    Non-GAAP SG&A expenses
    increased 30% YoY
    Q1 FY26

    Year-over-year change in non-GAAP SG&A expenses, driven by commercial investments.

    Acquired IP R&D expense
    $1 millionvs $20 million in Q1 2025
    Q1 FY26

    Acquired IP R&D expense for the first quarter.

    Pove IgAN Proteinuria Reduction
    52% from baseline49.8% reduction vs placebo
    36 weeks of treatment

    Reduction in proteinuria observed in the Pove IgAN RAINIER study at interim analysis.

    Pove IgAN Serum Gd-IgA1 Reduction
    77.4% from baseline79.3% reduction vs placebo
    36 weeks of treatment

    Reduction in serum Gd-IgA1 observed in the Pove IgAN RAINIER study at interim analysis.

    Pove IgAN Hematuria Resolution
    85.1%61.7% reduction vs placebo
    36 weeks of treatment

    Rate of hematuria resolution in Pove-treated patients in the IgAN RAINIER study.

    Pove IgAN Patients reaching UPCR < 0.5 g/g
    42.2%
    36 weeks of treatment

    Percentage of patients reaching an important clinical threshold for proteinuria in the Pove IgAN RAINIER study.

    Pove IgAN SAEs of infection
    0.5%observed in both placebo and Pove groups
    36 weeks of treatment

    Rate of serious adverse events of infection in the Pove IgAN RAINIER study, balanced between groups.

    CASGEVY patients initiated treatment
    Over 500
    since launch through Q1 FY26

    Cumulative number of patients who have initiated their CASGEVY treatment journey.

    JOURNAVX prescriptions filled
    350,000compared to ~550,000 in all of 2025
    Q1 FY26

    Number of JOURNAVX prescriptions filled in the first quarter, in line with expectations.

    JOURNAVX cumulative prescriptions written
    Over 1 million
    since launch

    Cumulative number of JOURNAVX prescriptions written since its launch.

    JOURNAVX payer coverage
    240 million lives
    Q1 FY26

    Number of lives covered by JOURNAVX payer agreements.

    JOURNAVX field force size
    300 representativesdoubled
    Q1 FY26

    Size of the JOURNAVX field force, which was doubled ahead of plan.

    IgAN patients in US & Europe
    150,000
    current

    Estimated patient population for IgAN in North America and Europe.

    Membranous patients in US & Europe
    100,000
    current

    Estimated patient population for primary membranous nephropathy in North America and Europe.

    AMKD AMPLITUDE population
    150,000
    current

    Estimated patient population for the AMPLITUDE study in AMKD.

    AMKD AMPLIFIED population (additional)
    100,000
    current

    Additional estimated patient population for the AMPLIFIED study in AMKD.

    ADPKD patients
    300,000
    current

    Estimated patient population for ADPKD.

    VX-407 treatable ADPKD patients
    10%
    current

    Percentage of ADPKD patients that VX-407 is designed to treat.

    Inaxaplin Phase II proteinuria reduction
    47.6%
    Phase II

    Proteinuria reduction observed in the Phase II study of inaxaplin.

    Pove IgAN BLA submission speed
    27 days
    Q1 FY26

    Record speed for BLA submission for Pove in IgAN.

    CF patients newly eligible (label expansion)
    approximately 800
    Q1 FY26

    Incremental commercial opportunity from recent label expansions for ALYFTREK and TRIKAFTA in the U.S.

    CF patients covered by ALYFTREK/TRIKAFTA labels
    about 95%
    Q1 FY26

    Percentage of people with CF now covered by the expanded ALYFTREK and TRIKAFTA labels.

    ALYFTREK sweat chloride reduction (2-5yo study)
    65%
    pivotal trial

    Remarkable result from the pivotal trial for ALYFTREK in patients 2 to 5 years of age.

    Zimislecel insulin-free patients
    10 out of 12
    after full dose and 1 year follow-up

    Results from the zimislecel study in type 1 diabetes, showing unprecedented insulin independence.

    IgAN patients not at KDIGO guideline goal
    about 75%
    current

    Percentage of IgAN patients in the U.S. who are not meeting the KDIGO guideline goal for proteinuria.

    Industry KPIs

    9
    MetricValueDetails
    Capital deployment$13 billionUSD
    Launch access metrics240 millionlives
    Pipeline read out calendar
    Product franchise net sales$1 billionUSD
    Regulatory approvals filings
    Peak long term sales guidance
    Prescription volume new starts350,000prescriptions
    Clinical trial efficacy safety data
    Cumulative patients uptake since launchOver 500patients

    Risks & headwinds

    2
    VX-522 tolerability issues

    Lung inflammation, inflammatory response to LNP

    Mitigation: Program discontinued; working with sites to close out the study.

    Tariff impact2026

    No material impact to income statement

    Mitigation: Company continues to evaluate the details of recent announcements and potential applicability to Vertex.

    Q&A highlights

    7

    What needs to happen for the renal franchise to rival CF in size, and which renal asset has the greatest long-term revenue potential?

    Reshma Kewalramani explained that the renal franchise targets common rare diseases (IgAN, membranous, AMKD, ADPKD) with hundreds of thousands of patients in Western markets. The diseases lead to severe outcomes (death, dialysis, transplantation), and Pove and inaxaplin have shown transformative potential. She highlighted Pove in IgAN as currently looking "sparkling" due to recent Phase III results.

    The reason I think that this has the potential to be as big, if not larger, than CF is that the diseases that these medicines treat are rare diseases, but they are common rare diseases.

    asked by Jessica Fye · answered by Reshma Kewalramani

    2 min read6 chapters

    Detailed Narrative

    01

    CF Label Expansions and Pipeline Progress

    Vertex achieved significant label expansions for ALYFTREK and TRIKAFTA in the U.S., now covering patients with at least one responsive CFTR gene variant, extending eligibility to about 95% of people with CF. Submissions for younger age groups (ALYFTREK 2-5 years, TRIKAFTA 1-2 years) are planned soon. The next-generation 3.0 CFTR modulators (VX-828, VX-581, VX-272) are progressing, with VX-828 results expected in H2 2026, aiming to further improve upon existing treatments.

    02

    Renal Franchise Development and Pove's Profile

    The renal franchise is rapidly establishing itself as Vertex's fourth, with four programs in mid- and late-stage development, including Pove in IgAN and primary membranous nephropathy, inaxaplin in AMKD, and VX-407 in ADPKD. Pove's potential best-in-class profile in IgAN stems from its engineered TACI fusion protein design, delivering optimal dual BAFF/APRIL inhibition, which has shown rapid, deep, and sustained improvement in proteinuria with a favorable safety profile and patient-friendly monthly subcutaneous administration.

    03

    Inaxaplin Program Updates and Strategic Decisions

    The pivotal Phase III AMPLITUDE study for inaxaplin in primary AMKD is on track for an interim analysis in early 2027, potentially leading to accelerated approval. The Phase IIb AMPLIFIED study, evaluating inaxaplin in AMKD patients with moderate proteinuria or type 2 diabetes, has completed enrollment with results expected in H2 2026. This strategic separation of patient populations was made early on to address their clear differences.

    04

    Type 1 Diabetes Program Resumption and Unprecedented Results

    Dosing in the Phase I/II/III study for zimislecel in type 1 diabetes has resumed following a manufacturing analysis. Previous clinical results demonstrated unprecedented🌐 outcomes, with 10 out of 12 patients becoming insulin-free after a full dose and one year of follow-up, particularly noteworthy for patients with long-standing T1D, undetectable endogenous insulin production, and severe hypoglycemic events.

    05

    JOURNAVX Commercial Momentum and Payer Progress

    JOURNAVX continues to build momentum with strong prescription growth, excellent physician and patient experiences, and expanding hospital and payer coverage. The field force has been doubled to 300 representatives, and a direct-to-patient telehealth platform (informed pain care) has been launched to enhance access. The company has secured coverage with two of the four major Medicare Part D plans, with a third close to agreement, positioning for gross-to-net normalization by year-end.

    06

    Renal Commercialization Preparations and Market Opportunity

    Vertex is investing in the nephrology community for the long term, preparing for the commercial launch of Povetacicept in IgAN. The strategy focuses on Pove's differentiated efficacy, tolerability, and patient-centric administration, supported by a specialty-sized renal field force, broad reimbursement efforts, and robust patient support programs. The IgAN market alone represents approximately 160,000 patients in the U.S., with a significant unmet need for effective treatments.

    AI-generated summary of the company’s earnings call. Not investment advice.